Welcome to our dedicated page for AgomAb Therapeutics NV SEC filings (Ticker: AGMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AgomAb Therapeutics NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AgomAb Therapeutics NV's regulatory disclosures and financial reporting.
Agomab Therapeutics NV Chief Medical Officer Philippe Constantin Wiesel reported his initial holdings of stock options on the company’s common shares. The filing lists ten option grants with exercise prices between $0.0005 and $14.26, expiring from 2029 through 2036. Footnotes explain which grants are already fully vested and which vest over time, and note that each American Depositary Share currently represents one common share.
Agomab Therapeutics ownership update: FMR LLC reports beneficial ownership of 4,873,680 shares, representing 10.0% of common stock as of the filing. The Schedule 13G shows sole dispositive and voting power reported by FMR LLC and dispositive power reported for Abigail P. Johnson.
The filing is a Schedule 13G disclosure, signed under powers of attorney and accompanied by Exhibit 99 referencing a 13d-1(k)(1) agreement; the signatures are dated 03/05/2026.
AgomAb Therapeutics NV received a Schedule 13D filing from investment entities LSP 7 Cooperatieve U.A. and LSP 7 Management B.V., which together report beneficial ownership of 5,141,992 common shares, representing about 10.6% of AgomAb’s 48,736,779 common shares outstanding as of February 9, 2026.
LSP 7 accumulated its position through pre-IPO preferred stock purchases of approximately €40 million that converted into 4,016,992 common shares at the IPO, plus a purchase of 1,125,000 American Depositary Shares at $16.00 per share on the IPO closing date. The investors are party to an amended and restated shareholders’ agreement providing registration rights for resale of certain shares and have agreed to a 180‑day lock-up restricting sales after the IPO closing.
The filing states that the investors may, from time to time, buy more shares, hold, or sell, and may discuss strategic alternatives with AgomAb’s management, board, other shareholders, and third parties, potentially including mergers, asset transactions, capital structure changes, or board composition changes. One of their designees, Felice Verduyn‑van Weegen, serves on AgomAb’s board of directors.
Agomab Therapeutics NV has completed its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market under the ticker “AGMB”. The ADSs were priced at $16.00 per ADS, generating aggregate gross proceeds of approximately $200.0 million before expenses.
The company also implemented amended and restated articles of association effective with the IPO and furnished related press releases covering the launch, pricing and closing of the offering.
AgomAb Therapeutics is conducting an initial public offering of $200,000,000 by offering 12,500,000 ADSs at $16.00 per ADS, with an underwriter option for up to 1,875,000 ADSs; ADSs will trade on Nasdaq under the symbol AGMB.
The prospectus states estimated net proceeds of approximately $181 million to advance clinical development of ontunisertib and AGMB-447, fund preclinical programs, a milestone payment related to the Origo acquisition, and general corporate purposes. The company is an emerging growth company and a foreign private issuer, reports under IFRS, and expects delivery of ADSs on February 9, 2026.